secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001193125-23-198578
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis Q2 revenue $95.0M; SYFOVRE sales $67.3M; net loss $122.0M
-----------------------------------------------------------------

- Total US net product revenue of $89.6M: SYFOVRE $67.3M (GA), EMPAVELI $22.3M (PNH).
- Net loss of $122.0M improved from $156.0M loss in Q2 2022; cash $616.3M.
- SYFOVRE reduced nonsubfoveal GA lesion growth up to 45% at Months 24-30 in GALE extension.
- Investigation of rare retinal vasculitis events found no drug product or manufacturing issues.
- R&D expenses $95.7M, G&A $111.4M; company funded into Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/0001193125-23-198578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/d532845d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-198578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer